Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Median-based incremental cost-effectiveness ratios with censored data.

Literature DB >> 26010599

Median-based incremental cost-effectiveness ratios with censored data.

Abstract

Cost-effectiveness is an essential part of treatment evaluation, in addition to effectiveness. In the cost-effectiveness analysis, a measure called the incremental cost-effectiveness ratio (ICER) is widely utilized, and the mean cost and the mean (quality-adjusted) life years have served as norms to summarize cost and effectiveness for a study population. Recently, the median-based ICER was proposed for complementary or sensitivity analysis purposes. In this article, we extend this method when some data are censored.

Entities: Chemical Disease Gene Species

Keywords: Censoring; ICER; cost-effectiveness analysis; median

Mesh：

Year: 2015 PMID： 26010599 PMCID： PMC4816674 DOI： 10.1080/10543406.2015.1052482

Source DB: PubMed Journal: J Biopharm Stat ISSN： 1054-3406 Impact factor: 1.051

31 in total

1. On estimating medical cost and incremental cost-effectiveness ratios with censored data.

Authors: H Zhao; L Tian
Journal: Biometrics Date: 2001-12 Impact factor: 2.571

2. Using inverse-weighting in cost-effectiveness analysis with censored data.

Authors: A R Willan; D Y Lin; R J Cook; E B Chen
Journal: Stat Methods Med Res Date: 2002-12 Impact factor: 3.021

3. Median regression with censored cost data.

Authors: Heejung Bang; Anastasios A Tsiatis
Journal: Biometrics Date: 2002-09 Impact factor: 2.571

4. The CE plane: a graphic representation of cost-effectiveness.

Authors: W C Black
Journal: Med Decis Making Date: 1990 Jul-Sep Impact factor: 2.583

Review 5. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Authors: Scott Ramsey; Richard Willke; Andrew Briggs; Ruth Brown; Martin Buxton; Anita Chawla; John Cook; Henry Glick; Bengt Liljas; Diana Petitti; Shelby Reed
Journal: Value Health Date: 2005 Sep-Oct Impact factor: 5.725

1. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.

Authors: Christophe Sapin; Ann Hartry; Siddhesh A Kamat; Maud Beillat; Ross A Baker; Anna Eramo
Journal: Drugs Context Date: 2016-09-23

1 in total

Median-based incremental cost-effectiveness ratios with censored data.

1. On estimating medical cost and incremental cost-effectiveness ratios with censored data.

2. Using inverse-weighting in cost-effectiveness analysis with censored data.

3. Median regression with censored cost data.

4. The CE plane: a graphic representation of cost-effectiveness.

Review 5. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.

Review 6. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

7. The usefulness of average cost-effective ratios.

8. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

9. Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.

10. Cost analysis with censored data.

1. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis.